Breast Cancer
Guardant Health Nabs FDA Approval for Liquid Biopsy CDx With Menarini Breast Cancer Drug
The firm's liquid biopsy assay Guardant360 CDx can now be used to identify patients eligible for treatment with Menarini's Orserdu in ESR1-mutant breast cancer.
Pathology Firm Paige Gets Microsoft Investment for Cloud-Based AI Dx
The firm plans to deliver clinical applications and computational biomarkers under the agreement, the terms of which were not immediately disclosed.
Guardant Health, Susan G. Komen Partner to Evaluate MRD Test in Breast Cancer
The test is designed to detect circulating tumor DNA in early-stage cancer patients after surgery to help oncologists identify those with residual or recurring disease.
Everything Genetic, Berkshire and Surrey Pathology Services Jointly Launch Cancer NGS Service in UK
BSPS will provide cancer sequencing services using two cancer gene panels currently under development at Everything Genetic to customers across the UK.
NewStem, MSK Innovation Hub Team to Validate Cancer Diagnostics Software Platform
The Israeli startup called this collaboration a necessary step toward commercializing its CE-marked NewStem Software Diagnostic Device for reducing oncology drug resistance.